Back to Journals » ClinicoEconomics and Outcomes Research » Volume 12

Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis

Total article views   Abstract views HTML views PDF downloads Totals
2,728 Dovepress* 2,180 255+ 913 2,435
PubMed Central* 0 293 93 293
Totals 2,180 548 1,006 2,728
*Since 15 April 2020
+Since July 2016

View citations on PubMed Central and Google Scholar